T he renin-angiotensin system is causally involved in a broad spectrum of cardiovascular diseases. Most of the known physiological and pathophysiological effects of angiotensin II are mediated by the angio tensin IItype 1 (AT1) receptor. The angiotensin IItype 2 (AT2) receptor is predominantly expressed in fetal and neonatal issues, is normally present only at low levels in adult myocardium, but is upregulated in the process of vascu lar and myocardial remodeling. After controversies about the existence and relevance of the AT2 receptor, it is today widely accepted that the AT2 receptor counteracts the AT1 receptor mediated action which in most cases is beneficial for the respec tive organs. 1 Several experiments in animals indicate that AT2 recep tor stimulation exerts antiproliferative effects on endothe lial and vascular smooth cells, and modifies left ventricular fibrogenic and growthstimulating responses. The recently developed nonpeptide AT2 receptor agonist "compound 21" emerged as a new tool to directly and selectively stimulate the AT2 receptor in vitro and in vivo. For example, com pound 21 had no effect on blood pressure, but improved the systolic and diastolic function postmyocardial infarction by antiapoptotic and antiinflammatory mechanisms. 2 Thus, in concordance with the vast majority of data obtained in the past with more conventional methods of studying the AT2 receptor, AT2 receptor agonism by compound 21 have been reported to exert cardio, nephro, and vasoprotective effects. 2 In humans, we lack of any pharmacological tool for direct and specific in vivo stimulation of the AT2 receptor. Hence, several research groups have used a genetic approach to over come this limitation. [3] [4] [5] The AT2 receptor gene is located on Xchromosome and the Gallele of the biallelic polymor phism +1675 G/A seems to be associated with enhanced transcription and expression of the AT2 receptor. Indeed, hypertensive Gallele carrier had a lower degree of left ven tricular hypertrophy, 3 an effect that is further modulated by salt intake. 4 The effects of AT2 receptor stimulation has been found in hypertensive subjects only.
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In this edition of the American Journal of Hypertension, the effect of genetic polymorphism of the AT2 receptor on athero sclerosis has been analyzed in patients with proven coronary artery disease. 5 It was found that expression and circulating levels of proinflammatory cytokines, soluble adhesion mol ecules, and acute phase response proteins reflecting systemic lowgrade inflammation were lower in Gallele than Aallele carriers. This effect on inflammatory markers was found only in males with hypertension. In accordance, in this case controlled study Gallele carriers had a decreased risk of coronary artery disease. The authors conclude that the AT2 receptor polymor phism affects the cardiovascular risk in preconditioned patients with hypertensive disease. 5 This conclusion is concordant to the previous observations that only in hypertensive subjects the AT2 receptor polymorphism modulates the development and extent of left ventricular hypertrophy. 3 The results of this casecontrol study are in part confirmatory, but it is important to have this confirmation and they also identify a new important pathogenetic mechanism of how AT2 receptor action modifies atherogenesis in humans (via subclinical inflammation).
Thus, in addition to the repetitive reports of functional con sequences of AT2 receptor in cardiac diseases, we now start to better understand the underlying mechanisms of AT2 receptor action on atherogenesis and we may soon have a new thera peutic tool in our hands (e.g., compound 21), that may exert cardio and vasoprotective properties in human cardiovascular disease.
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